Evaluation of SAR408701 in Patients With Advanced Solid Tumors

NCT ID: NCT02187848

Last Updated: 2025-02-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 254 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-23
• Study Completion Date: 2024-11-19

Brief Summary

Primary Objectives:

• To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 2 weeks (with and without a loading dose at Cycle 1) to patients with advanced solid tumors (Main Escalation and Loading Dose Escalation Q2W).
• To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 3 weeks to patients with advanced solid tumors (Escalation Q3W Cycle).
• To assess efficacy according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (Expansion Phase) when SAR408701 is administered once every 2 weeks with or without a loading dose at Cycle 1.

Secondary Objectives:

• To characterize the overall safety profile of SAR408701.
• To characterize the pharmacokinetic (PK) profile of SAR408701 and of its potential circulating derivatives.
• To identify the recommended phase 2 dose (RP2D) of SAR408701.
• To assess the potential immunogenicity of SAR408701.

Detailed Description

The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, and at least one follow-up visit after the end-of-treatment visit. Additional follow-up visits may be required until resolution or stabilization of adverse events (at least 30 days). Treatment may continue until precluded by toxicity, progression, or upon patient's request. If the patient stops study treatment for reason other than disease progression, follow-up visit will be performed every 3 months until disease progression or initiation of another anti-tumor treatment or death, whichever comes first.

Conditions

Neoplasm Malignant

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SAR408701 Main Dose Escalation Cohort

Dose escalation administered intravenously, once every two weeks

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Expansion Cohort colorectal cancer (CRC)

Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Expansion Cohort non-squamous NSCLC

Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Expansion Cohort gastric adenocarcinoma

Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Loading Dose Escalation cohorts (Escalation bis)

Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)

Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Expansion Cohort colorectal cancer (CRC-L)

Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Expansion Cohort small cell lung cancer (SCLC)

Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

SAR408701 Dose Escalation every 3 weeks cohort

Dose escalation administered intravenously, once every three weeks

Group Type: EXPERIMENTAL

SAR408701

Intervention Type: DRUG

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Interventions

SAR408701

Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Locally advanced or metastatic solid malignant tumor disease for which no standard alternative therapy is available.
• Availability of archived tumor tissue for carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 or CEA) testing.
• For participants in the Dose Escalation Cohorts (Main Escalation and Loading Dose Cohorts at every 2 week cycle and Dose Escalation every 3 week cycle): patients with tumors expressing or likely to be expressing CEACAM5 which includes colorectal cancer (CRC), non-squamous non-small cell lung cancer (NSCLC), gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, cholangiocarcinoma, epithelial ovarian cancer and endometrial adenocarcinoma are favored, or if carcinoembryonic antigen (CEA) plasma levels >5 ng/mL.
• For participants to the Expansion Phase cohorts: patients with CRC or with CEACAM5 positive non-squamous NSCLC, small cell lung cancer (SCLC) or gastric carcinoma (including esophago-gastric junction adenocarcinoma of the Siewert types II and III).
• At least one measurable lesion by RECIST v1.1 in the Expansion Phase only.
• At least one lesion amenable to biopsy (Expansion cohort - CRC and gastric cancer only). Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy.
• Signed informed consent.

Exclusion Criteria

• Aged less than 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status more than 1.
• New or progressing brain involvement.
• Concurrent treatment with any other anticancer therapy or inadequate wash-out period for prior anticancer therapies before first administration of SAR408701, or non-resolution of toxicities induced by these anticancer therapies.
• Female or male patients with reproductive potential who do not agree to use an accepted effective method of contraception during the study treatment period and for at least 3 months following completion of study treatment.
• Pregnancy or breast-feeding.
• Participation to any clinical research study evaluating another investigational drug or therapy within 3 weeks of initiation of study regimen.
• Prior therapy targeting CEACAM5.
• Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates).
• Poor bone marrow reserve resulting in low blood cell counts.
• Poor kidney and liver functions.
• Any of the following within 6 months prior to study enrolment: infectious or inflammatory bowel disease, diverticulitis, gastrointestinal perforation, intestinal obstruction, and gastrointestinal hemorrhage. Patients with malabsorption syndrome are excluded.
• Previous history and or unresolved corneal disorders. The use of contact lenses is not permitted.
• Unresolved signs and symptoms of neuropathy; Grade 1 is acceptable if prior neurotoxic drugs such as cisplatin or taxanes.
• Abnormal cardiac function defined by a left ventricular ejection fraction (LVEF) of <50%.
• Cardiac conduction defects, or any other clinically significant arrhythmias.
• Known intolerance to infused protein products.
• Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYPs) enzymes and for which a dose reduction cannot be considered.
• Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before 1st administration of SAR408701.
• Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid as per package insert of each drug, including the following: increase intraocular pressure, prior or current glaucoma, narrow-angle glaucoma, ongoing eye infection, uncontrolled hypertension, known/suspected allergy to constituents of the preparation (such as sodium bisulfite).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Yale University School of Medicine Site Number : 840002

New Haven, Connecticut, United States

Dana Farber Cancer Institute- Site Number : 840005

Boston, Massachusetts, United States

Investigational Site Number : 124001

Toronto, Ontario, Canada

Investigational Site Number : 250003

Bordeaux, , France

Investigational Site Number : 250006

Dijon, , France

Investigational Site Number : 250004

Marseille, , France

Investigational Site Number : 250007

Rennes, , France

Investigational Site Number : 250005

Saint-Mandé, , France

Investigational Site Number : 250002

Toulouse, , France

Investigational Site Number : 250001

Villejuif, , France

Investigational Site Number : 410002

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 410005

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 410003

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 410004

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 410001

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 724001

Barcelona, Barcelona [Barcelona], Spain

Investigational Site Number : 724002

Majadahonda, Madrid, Spain

Investigational Site Number : 724003

Madrid, Madrid, Comunidad de, Spain

Investigational Site Number : 724004

Madrid / Madrid, Madrid, Comunidad de, Spain

Investigational Site Number : 724006

Madrid, , Spain

Countries

United States; Canada; France; South Korea; Spain

References

Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, Demers B, Fagniez N, Henry C, Hospitel M, Soria JC, Tabernero J. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10.

Reference Type: RESULT

PMID: 35026412 (View on PubMed)

Tabernero J, Bedard PL, Bang YJ, Vieito M, Ryu MH, Fagniez N, Chadjaa M, Soufflet C, Masson N, Gazzah A. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Res Commun. 2023 Aug 28;3(8):1662-1671. doi: 10.1158/2767-9764.CRC-23-0284. eCollection 2023 Aug.

Reference Type: RESULT

PMID: 37645622 (View on PubMed)

Other Identifiers

U1111-1153-3461

Identifier Type: REGISTRY

Identifier Source: secondary_id

2014-001130-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TED13751

Identifier Type: -

Identifier Source: org_study_id